Ben Davidson
#162,217
Most Influential Person Now
Researcher
Ben Davidson's AcademicInfluence.com Rankings
Ben Davidsonengineering Degrees
Engineering
#7032
World Rank
#8391
Historical Rank
Electrical Engineering
#2161
World Rank
#2267
Historical Rank
Ben Davidsoncomputer-science Degrees
Computer Science
#9424
World Rank
#9898
Historical Rank
Computational Linguistics
#2275
World Rank
#2298
Historical Rank
Machine Learning
#4120
World Rank
#4169
Historical Rank
Artificial Intelligence
#4462
World Rank
#4523
Historical Rank
Download Badge
Engineering Computer Science
Ben Davidson's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Ben Davidson Influential?
(Suggest an Edit or Addition)Ben Davidson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Snail, Slug, and Smad‐interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma (2005) (441)
- Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance (2011) (400)
- MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer (2008) (367)
- Notch3 gene amplification in ovarian cancer. (2006) (280)
- Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer (2013) (243)
- Transcriptional Gene Silencing Promotes DNA Hypermethylation through a Sequential Change in Chromatin Modifications in Cancer Cells (2004) (236)
- High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma (2004) (187)
- Laminin-Induced Signaling in Tumor Cells (2004) (170)
- The Role of Desmin and N-Cadherin in Effusion Cytology: A Comparative Study Using Established Markers of Mesothelial and Epithelial Cells (2001) (166)
- Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. (2010) (165)
- Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR) (2015) (152)
- EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma (2004) (152)
- Epithelial–Mesenchymal Transition in Ovarian Carcinoma (2012) (151)
- Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer (2010) (150)
- Borderline tumors of the ovary (1998) (142)
- NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. (2006) (140)
- Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. (2005) (139)
- Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. (2005) (138)
- HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer (2015) (131)
- Laminin-induced signaling in tumor cells. (2005) (128)
- MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. (1999) (127)
- A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival (2006) (125)
- Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. (2008) (120)
- High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations (2018) (120)
- Exosome-derived miRNAs and ovarian carcinoma progression. (2014) (119)
- Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. (2015) (117)
- Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22‐translocation (2013) (115)
- Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. (2010) (114)
- ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity (2017) (111)
- miRNA profiling along tumour progression in ovarian carcinoma (2011) (111)
- Expression of E-cadherin transcriptional regulators in ovarian carcinoma (2006) (110)
- Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. (2003) (109)
- Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. (2008) (109)
- Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma (2006) (106)
- The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma (2002) (105)
- Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker (2014) (104)
- Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. (2005) (104)
- Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas (2013) (101)
- E‐cadherin and α‐, β‐, and γ‐catenin protein expression is up‐regulated in ovarian carcinoma cells in serous effusions (2000) (100)
- Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies (1999) (99)
- European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery (2016) (96)
- Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. (2001) (96)
- Granulin‐epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma (2004) (95)
- HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. (2005) (94)
- Fine‐needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions (2003) (92)
- European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery (2017) (92)
- S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. (2013) (91)
- Cystic change in metastatic lymph nodes: A common diagnostic pitfall in fine‐needle aspiration cytology (2002) (90)
- Borderline ovarian tumours. (2012) (87)
- CA 125 measurement and ultrasonography in borderline tumors of the ovary. (2000) (85)
- Novel Fusion of MYST/Esa1-Associated Factor 6 and PHF1 in Endometrial Stromal Sarcoma (2012) (85)
- Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma (2010) (84)
- The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. (2006) (83)
- Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. (2008) (81)
- Malignant effusions: From diagnosis to biology (2004) (81)
- Guidelines for the cytopathologic diagnosis of epithelioid and mixed‐type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology (2015) (80)
- Altered Expression and Activation of the Nerve Growth Factor Receptors TrkA and p75 Provide the First Evidence of Tumor Progression to Effusion in Breast Carcinoma (2004) (79)
- Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma (2006) (79)
- Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation. (2014) (79)
- Ovarian Cancer: Diagnostic, Biological and Prognostic Aspects (2014) (76)
- Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. (2012) (75)
- Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions (2010) (73)
- Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): Co-expression in metastatic serous ovarian carcinoma (2004) (72)
- Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. (2010) (72)
- Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma (2007) (71)
- Altered Expression of Metastasis-Associated and Regulatory Molecules in Effusions from Breast Cancer Patients (2004) (71)
- Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling (2006) (70)
- Gene expression signatures of primary and metastatic uterine leiomyosarcoma. (2014) (70)
- αV- and β1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients (2003) (70)
- Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. (2001) (68)
- Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. (2000) (68)
- Infertility treatment after conservative management of borderline ovarian tumors (2001) (68)
- Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas (2010) (66)
- RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12) (2013) (66)
- The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells (2008) (65)
- Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. (2009) (65)
- MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma. (2014) (64)
- MicroRNAs in Ovarian Cancer. (2015) (64)
- Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. (2009) (63)
- Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature (2004) (61)
- Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. (2001) (60)
- MITOGEN-ACTIVATED PROTEIN KINASES (MAPK) AS PREDICTORS OF CLINICAL OUTCOME IN SEROUS OVARIAN CARCINOMA IN EFFUSIONS (2003) (58)
- Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: A possible activation pathway? (2003) (58)
- Homozygous deletion of MKK4 in ovarian serous carcinoma (2006) (58)
- Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. (2007) (58)
- Primary primitive neuroectodermal tumor of the cauda equina. (2000) (57)
- Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma (2009) (57)
- Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. (2016) (56)
- Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. (2001) (56)
- Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. (2014) (55)
- Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. (1998) (55)
- Pathogenesis of ovarian cancer: clues from selected overexpressed genes. (2009) (55)
- Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study. (2001) (55)
- Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study. (2000) (54)
- The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. (2015) (53)
- Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma (2015) (53)
- Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology (2015) (53)
- Expression of Matrix Metalloproteinase-9 in Squamous Cell Carcinoma of the Uterine Cervix—Clinicopathologic Study Using Immunohistochemistry and mRNAin SituHybridization (1999) (52)
- Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma (2012) (52)
- Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. (2001) (51)
- Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. (1999) (50)
- Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions (2004) (49)
- Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. (2002) (48)
- Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. (2011) (48)
- E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. (2000) (48)
- Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. (2006) (48)
- Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. (2003) (48)
- PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. (2003) (48)
- Ets-1 mRNA Expression in Effusions of Serous Ovarian Carcinoma Patients Is a Marker of Poor Outcome (2001) (47)
- Cytogenetic and molecular profile of endometrial stromal sarcoma (2016) (47)
- Macrophage infiltration and angiogenesis in cervical squamous cell carcinomaclinicopathologic correlation (1999) (46)
- Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". (2009) (46)
- Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. (2004) (46)
- Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings (2000) (46)
- Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma – diagnostic and prognostic implications (2004) (46)
- E-Cadherin complex protein expression and survival in ovarian carcinoma. (2000) (46)
- Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. (2010) (45)
- The biological role and regulation of matrix metalloproteinases (MMP) in cancer. (2002) (45)
- The clinical and diagnostic role of microRNAs in ovarian carcinoma. (2014) (45)
- Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. (2008) (44)
- The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. (2004) (44)
- Prognostic biomarkers in endometrial and ovarian carcinoma (2014) (44)
- Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. (2004) (43)
- Biological characteristics of cancers involving the serosal cavities. (2007) (43)
- Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. (2006) (43)
- The Role of the Tumor Stroma in Ovarian Cancer (2014) (42)
- BAG-4/SODD and Associated Antiapoptotic Proteins Are Linked to Aggressiveness of Epithelial Ovarian Cancer (2007) (42)
- Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma (2007) (42)
- Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. (2007) (41)
- Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma (2007) (41)
- Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. (2010) (41)
- D2-40 is Not a Specific Marker for Cells of Mesothelial Origin in Serous Effusions (2006) (40)
- Expression and Clinical Role of Antiapoptotic Proteins of the Bag, Heat Shock, and Bcl-2 Families in Effusions, Primary Tumors, and Solid Metastases in Ovarian Carcinoma (2009) (40)
- MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells (2007) (39)
- The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma (2011) (39)
- Ovarian Carcinoma and Serous Effusions. Changing Views Regarding Tumor Progression and Review of Current Literature (2001) (39)
- Dissociated Expression of Bcl-2 and Ki-67 in Endometrial Lesions: Diagnostic and Histogenetic Implications (2002) (39)
- Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. (2004) (38)
- Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells’ sensitivity to paclitaxel (2016) (38)
- Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters. (2009) (38)
- Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. (2013) (38)
- The diagnostic role of claudins in serous effusions. (2007) (37)
- IKK-ε coordinates invasion and metastasis of ovarian cancer. (2012) (36)
- Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. (2012) (36)
- Inflammatory Response in Cervicallntraepithelial Neoplasia and Squamous Cell Carcinoma of the Uterine Cervix (1997) (36)
- Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. (2011) (36)
- Large Scale Genomic Instability as an Additive Prognostic Marker in Early Prostate Cancer (2009) (35)
- CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma (2015) (34)
- Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma (2006) (34)
- AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. (2003) (33)
- Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions (2010) (33)
- Adenomatous Polyposis Coli (APC) Protein Expression in Primary and Metastatic Serous Ovarian Carcinoma (2002) (33)
- Prognostic factors in malignant pleural mesothelioma. (2015) (33)
- Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma (2005) (33)
- Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma (2004) (33)
- The role of flow cytometric immunophenotyping in improving the diagnostic accuracy in referred fine‐needle aspiration specimens (2004) (33)
- Expression of Metalloproteinases and Their Inhibitors in Adenocarcinoma of the Uterine Cervix (1998) (32)
- Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. (2013) (32)
- Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications. (2001) (32)
- HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases (2012) (32)
- Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma. (2016) (31)
- The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions (2004) (31)
- Different Expression and Clinical Role of S100A4 in Serous Ovarian Carcinoma at Different Anatomic Sites (2009) (31)
- Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. (2007) (31)
- Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers (2020) (30)
- Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? (2012) (30)
- Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva (2013) (30)
- Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients (2005) (30)
- Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis. (1999) (30)
- The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. (2006) (29)
- RETRACTED: Molecular based treatment of oral cancer (2003) (29)
- The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. (2006) (28)
- Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. (2012) (28)
- SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions. (2012) (28)
- Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. (2015) (28)
- Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours – A prognostic test after surgical resection (2015) (28)
- Inflammatory response in cervical intraepithelial neoplasia and squamous cell carcinoma of the uterine cervix. (1997) (28)
- Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction. (1999) (28)
- HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. (2013) (27)
- Cadherin Expression in Ovarian Carcinoma and Malignant Mesothelioma Cell Effusions (2006) (27)
- Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant versus Benign Effusions (2007) (27)
- Caveolin-1 expression in ovarian carcinoma is MDR1 independent. (2002) (27)
- L1CAM as a prognostic marker in stage I endometrial cancer: a validation study (2016) (27)
- Identification of an EPC2-PHF1 fusion transcript in low-grade endometrial stromal sarcoma (2018) (27)
- Expression of topoisomerase II and Ki‐67 in cervical carcinoma — clinicopathological study using immunohistochemistry (2000) (27)
- Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. (2011) (27)
- APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. (2014) (27)
- Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry (2008) (27)
- Primary ovarian angiosarcoma presenting as malignant cells in ascites: Case report and review of the literature (2005) (27)
- Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. (2001) (26)
- Flow cytometric immunphenotyping of epithelial cancer cells in effusions—Technical considerations and pitfalls (2007) (26)
- Expression of the 67 kDa laminin receptor and the α6 integrin subunit in serous ovarian carcinoma (2004) (25)
- SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma. (2019) (25)
- Recently identified drug resistance biomarkers in ovarian cancer (2016) (25)
- White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk (2018) (24)
- Expression and Clinical Role of Growth Differentiation Factor-15 in Ovarian Carcinoma Effusions (2010) (24)
- CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival. (2010) (24)
- Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. (2008) (23)
- Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup (2016) (23)
- Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. (2010) (23)
- Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. (2013) (23)
- The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. (2006) (23)
- Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. (2008) (23)
- Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities (2008) (23)
- Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial (2017) (23)
- Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. (2017) (22)
- The Anti-Apoptotic Activity of BAG3 Is Restricted by Caspases and the Proteasome (2009) (22)
- Biological effects induced by insulin‐like growth factor binding protein 3 (IGFBP‐3) in malignant melanoma (2010) (22)
- The high post‐test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant (2006) (22)
- The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma. (2007) (22)
- Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions. (2005) (22)
- Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. (2009) (22)
- BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma (2014) (22)
- Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. (2016) (22)
- Expression of angiogenesis-related genes in ovarian carcinoma – A clinicopathologic study (2004) (22)
- MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. (2012) (21)
- New determinates of disease progression and outcome in metastatic ovarian carcinoma. (2010) (21)
- Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome (2012) (21)
- Involvement of DPP9 in gene fusions in serous ovarian carcinoma (2017) (21)
- Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index (2012) (21)
- Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed‐Type Malignant Mesothelioma: a secondary publication (2015) (21)
- Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells. (2011) (21)
- Mitogen‐activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells (2005) (20)
- Ezrin Is Associated with Disease Progression in Ovarian Carcinoma (2016) (20)
- CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. (2016) (20)
- Angiogenic Molecule Expression is Downregulated in Effusions from Breast Cancer Patients (2005) (20)
- Detection of monocyte/macrophage cell populations in effusions: A comparative study using flow cytometric immunophenotyping and immunocytochemistry (2001) (20)
- Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. (2012) (20)
- Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. (2007) (20)
- Nucleoside transporters are widely expressed in ovarian carcinoma effusions (2012) (20)
- Molecular based treatment of oral cancer. (2003) (20)
- HMGA2 expression pattern and TERT mutations in tumors of the vulva (2015) (19)
- Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. (2007) (19)
- Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. (2008) (19)
- Matched Gene Selection and Committee Classifier for Molecular Classification of Heterogeneous Diseases (2010) (19)
- Expression and Clinical Role of Protein of Regenerating Liver (PRL) Phosphatases in Ovarian Carcinoma (2011) (19)
- RNA‐sequencing identifies novel GREB1‐NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13) (2017) (19)
- Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping (2005) (19)
- Genomic aberrations in borderline ovarian tumors (2010) (19)
- Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids (2012) (19)
- Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. (2007) (19)
- Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas (2017) (18)
- Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling. (2005) (18)
- Fine‐needle aspiration cytology of the thyroid gland: Comparative analysis of experience at three hospitals (2006) (18)
- Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. (2009) (18)
- Flow cytometric immunophenotyping of cancer cells in effusion specimens: Diagnostic and research applications (2007) (18)
- New Diagnostic and Molecular Characteristics of Malignant Mesothelioma (2008) (18)
- Angiogenesis in Uterine Cervical Intraepithelial Neoplasia and Squamous Cell Carcinoma: An Immunohistochemical Study (1997) (18)
- Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status (2011) (18)
- Activation of NF- κ B Signaling by Inhibitor of NF- κ B Kinase β Increases Aggressiveness of Ovarian Cancer (2010) (18)
- REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker (2016) (18)
- VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. (2014) (17)
- Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma. (2013) (17)
- Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer (2012) (17)
- Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. (2005) (17)
- Expression of extracellular matrix proteins in cervical squamous cell carcinoma--a clinicopathological study. (1998) (17)
- Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure (2012) (17)
- Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva (2016) (16)
- Breast Carcinoma Cells in Primary Tumors and Effusions Have Different Gene Array Profiles (2009) (16)
- Expression and clinical role of long non-coding RNA in high-grade serous carcinoma. (2018) (16)
- Genomic profile of ovarian carcinomas (2014) (16)
- Cell survival and apoptosis‐related molecules in cancer cells in effusions: A comprehensive review (2009) (15)
- The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas (2018) (15)
- ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. (2019) (15)
- The diagnostic role of BAP1 in serous effusions. (2018) (15)
- Molecular characteristics of uterine sarcomas (2017) (15)
- Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression (2017) (14)
- Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma (2015) (14)
- HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. (2016) (14)
- Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions (2000) (14)
- MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. (2016) (14)
- Expression of matrix proteins in uterine cervical neoplasia using immunohistochemistry. (1998) (13)
- DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium (2012) (13)
- Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma (2012) (13)
- Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort* (2013) (13)
- Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes (2019) (13)
- Low Frequency of ESRRA–C11orf20 Fusion Gene in Ovarian Carcinomas (2014) (13)
- Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women’s Cancers (2015) (13)
- BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma. (2016) (13)
- Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13). (2015) (12)
- Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. (2013) (12)
- Netrin‐4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors (2011) (12)
- CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model (2020) (12)
- The diagnostic and research applications of flow cytometry in cytopathology (2012) (12)
- PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. (2012) (12)
- Reproducibility of measurement of myometrial invasion in endometrial carcinoma (2016) (12)
- Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective (2012) (11)
- Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing (2019) (11)
- Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities (2005) (11)
- PINCH‐2 expression in cancers involving serosal effusions using quantitative PCR (2011) (11)
- Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. (2011) (11)
- Fine‐needle aspiration cytology of lobular carcinoma in situ (2002) (11)
- The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma. (2006) (11)
- DNA Ploidy Heterogeneity in Endometrial Carcinoma: Comparison Between Curettage and Hysterectomy Specimens (2010) (10)
- Biomarkers of drug resistance in ovarian cancer – an update (2019) (10)
- Malignant Nonhematological Effusion Characterization by Flow Cytometry (2016) (10)
- MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. (2016) (10)
- Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays (2011) (10)
- AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma (2013) (10)
- TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma. (2017) (9)
- Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas—an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications (2009) (9)
- Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways (2019) (9)
- Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma (2018) (9)
- Doxorubicin levels in the serum and ascites of patients with ovarian cancer. (2007) (9)
- Expression of rasGTPase activating protein in basal cell carcinoma of the skin. (1998) (8)
- Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma (2021) (8)
- Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer (2019) (8)
- Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma (2017) (7)
- Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response (2019) (7)
- A novel truncated form of HMGA2 in tumors of the ovaries. (2016) (7)
- Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. (2008) (7)
- Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only (2018) (7)
- Ulex Europaeus Lectin and Anti‐CD31 Staining in Squamous Cell Carcinoma of the Uterine Cervix: Potential Prognostic Markers (1998) (7)
- Immunohistochemical analysis of rasGTPase activating protein (rasGAP) in prostate cancer. (1998) (7)
- Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases. (2013) (6)
- Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer. (2020) (6)
- Ovarian carcinoma cells in effusions show increased S‐phase fraction compared to corresponding primary tumors (2008) (6)
- Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma (2018) (6)
- A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis (2017) (6)
- Molecular testing on serous effusions (2020) (6)
- Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma. (2017) (6)
- Epithelial–mesenchymal transition markers in malignant ovarian germ cell tumors (2017) (6)
- The Chemokine Receptor CXCR4 is More Frequently Expressed in Breast Compared to Other Metastatic Adenocarcinomas in Effusions (2008) (5)
- Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas (2018) (5)
- DISSOCIATED MRNA EXPRESSION OF THE 67KDA LAMININ RECEPTOR AND THE ALPHA 6 INTEGRIN SUBUNIT IN SEROUS OVARIAN CARCINOMA (2003) (5)
- MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer. (2017) (5)
- Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei (2021) (5)
- CD44 expression in uterine cervical intraepithelial neoplasia and squamous cell carcinoma: an immunohistochemical study. (1998) (5)
- Chromosome 19 rearrangements in ovarian carcinomas: Zinc finger genes are particularly targeted (2014) (5)
- Soluble AXL is ubiquitously present in malignant serous effusions. (2019) (5)
- Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma (2020) (5)
- Kallikrein 4 is expressed in malignant mesothelioma—Further evidence for the histogenetic link between mesothelial and epithelial cells (2007) (5)
- The diagnostic role of PTEN and ARID1A in serous effusions (2018) (5)
- Role of the Exosome Secretion Machinery in Ovarian Carcinoma: In Vitro and In Vivo Models (2020) (4)
- Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer (2020) (4)
- Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy (2021) (4)
- Expression of Cancer-Associated Molecules in Malignant Mesothelioma (2007) (4)
- Hepatocyte nuclear factor‐1β is not a specific marker of clear cell carcinoma in serous effusions (2014) (4)
- Bilateral ovarian carcinomas differ in the expression of metastasis-related genes (2016) (4)
- Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale (2021) (3)
- Translational proof of mechanism (PoM) for sorafenib with bevacizumab: Endpoint analysis and clinical activity. (2009) (3)
- Abstract A32: PBX1, a transcriptional regulator, promotes stemness and chemoresistance in ovarian cancer. (2016) (3)
- Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers (2022) (3)
- The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma (2020) (3)
- The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high‐grade serous carcinoma (2020) (3)
- Flow cytometric measurement of cellular FLICE‐inhibitory protein (c‐FLIP) in ovarian carcinoma effusions (2011) (3)
- MOC31PE immunotoxin – targeting peritoneal metastasis from epithelial ovarian cancer (2017) (3)
- Molecular characterization of carcinosarcomas arising in the uterus and ovaries (2019) (3)
- Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model (2021) (3)
- Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma. (2018) (3)
- Expression of palladin is associated with disease progression in metastatic high‐grade serous carcinoma (2020) (2)
- Chromatin Modifications in Cancer Cells Hypermethylation through a Sequential Change in Transcriptional Gene Silencing Promotes DNA (2004) (2)
- Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression. (2005) (2)
- Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies (2018) (2)
- Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and Origins (2015) (2)
- Expression of 14‐3‐3 sigma and eta proteins is unrelated to survival in metastatic high‐grade serous carcinoma (2018) (2)
- A Novel Cryptic t(2;3)(p21;q25) Translocation Fuses the WWTR1 and PRKCE Genes in Uterine Leiomyoma With 3q- as the Sole Visible Chromosome Abnormality (2022) (2)
- Recurrent fusion transcripts in squamous cell carcinomas of the vulva (2017) (2)
- Malignant Mesothelioma (2004) (2)
- Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma (2021) (2)
- MGMT promoter methylation is a rare epigenetic change in malignant effusions (2019) (2)
- Can the classification of low-grade endometrial stromal tumors still be improved? (2018) (2)
- Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis (2021) (2)
- Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma (2020) (2)
- Proteomics in cancer. (2004) (2)
- TGFβ splicing and canonical pathway activation in high-grade serous carcinoma (2017) (2)
- Abstract 5170: The autotaxin-lysophosphatidic acid signaling pathways in ovarian carcinoma (2015) (1)
- Ovarian/Primary Peritoneal Carcinoma (2012) (1)
- Abstract 517: LncRNA expression at the different site of high-grades serous carcinoma (2018) (1)
- Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile (2022) (1)
- Molecular Cytology of Serous Effusions (2018) (1)
- Molecular Genetic Markers in Female Reproductive Cancers (2011) (1)
- Genomic profile of ovarian carcinomas (2014) (1)
- The Biological Role of the Long Non-coding RNA LINK-A in Ovarian Carcinoma (2020) (1)
- Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies (2022) (1)
- Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study (2022) (1)
- Abstract LB-189: BIRC5 (Survivin) is a prognostic biomarker and potential drug target for patients with malignant peripheral nerve sheath tumors. (2013) (1)
- Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma (2020) (1)
- Papilloma of the Fallopian Tube: A Rare Gynecologic Neoplasm Harboring a BRAF (c.1799T>A) Mutation (V600E) (2019) (1)
- Endometrial Cancer—Pathology and Genetics (2014) (1)
- The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma (2020) (1)
- Fusion of the HMGA2 and BNC2 Genes in Uterine Leiomyoma With t(9;12)(p22;q14) (2022) (1)
- Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker (2014) (1)
- Clinicopathological prognostic parameters in patients with tubo‐ovarian carcinoma effusions (2022) (1)
- 56 Chemokine receptors are rarely expressed on malignant or benign mesothelial cells (2006) (1)
- Retraction notice to 'Molecular based treatment of oral cancer' [Oral Oncol. 39 (2003) 749-758]. (2007) (1)
- Cell adhesion and matrixassociated proteins in ovarian carcinoma (2007) (0)
- Systems Biology Studies of Gene Network and Cell Signaling Pathway in Cancer Research (2013) (0)
- Inside this Month’s Cytopathology (2021) (0)
- Galaxy and the full spectrum of needs in a small-scale cancer study (2017) (0)
- EP889 Improved cytoreduction of ovarian cancer using CD24-targeted fluorescence image-guided surgery in a preclinical murine model (2019) (0)
- Abstract CT055: Novel intraperitoneal treatment for peritoneal metastases: results from the Immunotoxin in Peritoneal Carcinomatosis (ImmunoPeCa) phase I clinical trial (2016) (0)
- Author's response to reviews Title: The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells Authors: (2008) (0)
- Abstract LB-51: Correlation of expression of MDR-associated genes with outcome in primary ovarian serous carcinoma (2010) (0)
- 2022-RA-953-ESGO Serine metabolism remodeling after platinum-based chemotherapy is a new vulnerability in resistant ovarian cancer patients (2022) (0)
- Gene Expression Signatures Differentiate Ovarian / Peritoneal Serous Carcinoma from DiffuseMalignant Peritoneal Mesothelioma (2006) (0)
- 0199: The Activated Nerve Growth Factor Receptor P-Trka is Selectively Expressed in Advanced Stage Ovarian Carcinoma (2006) (0)
- Preclinical analysis of IGF-IR antibody MK-0646 in endometrial cancer (2010) (0)
- Molecular Genetics of Uterine Sarcomas (2019) (0)
- Editorial Malignant Mesothelioma (2004) (0)
- Nuclear SYK phosphorylation is associated with poor survival in high-grade serous ovarian cancer (2017) (0)
- Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness (2022) (0)
- DNA methylation profiles in ovarian serous neoplasms nd their implications in ovarian carcinogenesis (2010) (0)
- Splice-Variant Knock-Out of TGFβ Receptors Perturbates the Proteome of Ovarian Carcinoma Cells (2021) (0)
- 414 Prognostic factors related to recurrence and survival of early stage vulvar squamous cell carcinoma (2020) (0)
- Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer (2012) (0)
- Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D (2022) (0)
- Mini-review Laminin-induced signaling in tumor cells (2005) (0)
- Abstract 401: Gene expression signatures differentiate primary and metastatic uterine leiomyosarcoma. (2013) (0)
- O392 Identification of genomic alterations of human ovarian carcinoma with genome‐wide copy number analysis (2009) (0)
- Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids (2012) (0)
- Expression of the chromatin remodeling factor Rsf-1 in breast carcinoma effusions predicts poor survival (2007) (0)
- 508 Alternative splicing of Lysyl Oxidase-Like 4 in ovarian carcinoma (2010) (0)
- 440: Genomic copy number changes and the prognostic impact of the encoded genes PTEN and BIRC5 in malignant peripheral nerve sheath tumours (2014) (0)
- 14 The long-term oncologic outcomes of minimally invasive surgery (robot-assisted/laparoscopic) versus abdominal radical hysterectomy for early-stage cervical cancer patients treated between 2000 and 2017 at the OSLO university hospital (2019) (0)
- Death-domain-associated protein (DAXX) is a novel prognostic factor in metastatic high-grade serous carcinoma (2020) (0)
- Metabolomic characterization of ovarian serous carcinoma effusions : 1 chemotherapy-related effects and comparison with malignant mesothelioma and breast 2 carcinoma 3 (2017) (0)
- Abstract NTOC-115: ASSOCIATION BETWEEN NUCLEAR SYK PHOSPHORYLATION AND EGFR/ERBB2 PATHWAY AND POOR SURVIVAL IN HIGH GRADE SEROUS OVARIAN CANCER (2017) (0)
- Molecular characteristics of low‐grade serous carcinoma in effusions (2023) (0)
- Malignant-Secondary (MAL-S) (2020) (0)
- HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer (2015) (0)
- Abstract 3147: Alternative splicing of Lysyl Oxidase-like 4 in ovarian carcinoma (2010) (0)
- Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma. (2023) (0)
- Primary cytoreductive surgery or neoadjuvant chemotherapy: A retrospective analysis of 214 patients with stage IIIc and IV ovarian, tubal and peritoneal cancer from the Norwegian Radium Hospital (2007) (0)
- 386 Unique MiRNA Signature and Oncogenic Potential of Effusion Fluid-derived Exosomes From Ovarian Carcinoma Patients (2012) (0)
- The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas (2018) (0)
- 2022-RA-717-ESGO Establishment of peritoneal dECM scaffolds for 3D culture of ovarian cancer organoids (2022) (0)
- Abstract C158: IKKβ inhibition modulates NF‐κB signaling and decreases aggressiveness of ovarian cancer (2009) (0)
- CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma (2015) (0)
- Abstract 815: The role of spleen tyrosine kinase (SYK) in paclitaxel resistant ovarian cancer (2012) (0)
- Abstract 3197: Exosome secretion in ovarian carcinoma (2015) (0)
- Abstract 2068: Profile, target genes and regulation of microRNAs in ovarian carcinoma tumor progression (2010) (0)
- Abstract LB-50: Overexpression ofPBX1is associated with recurrence and worse clinical outcome in patients with recurrent ovarian high-grade serous carcinoma (2010) (0)
- Gene may predict aggressive ovarian cancer (2005) (0)
- 156 Profile, target genes and regulation of microRNAs in ovarian carcinoma tumour progression (2010) (0)
- [Molecular biology of human papilloma virus infection of the female genital tract]. (1995) (0)
- With Thanks to the International Journal of Gynecological Cancer: Reviewers of 2011 (2011) (0)
- L1CAM as a prognostic marker in stage I endometrial cancer: a validation study (2016) (0)
- Abstract 5166: THE WNT SIGNALING PATHWAY IN THE OVARIAN CARCINOMA (2015) (0)
- Inside this Month's Cytopathology (2023) (0)
- Abstract 2031: The noncanonical pathways of transforming growth factor β in ovarian carcinoma (2018) (0)
- Abstract 5182: Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma (2018) (0)
- 2022-RA-1306-ESGO Effect of the COVID-19 pandemic on primary therapy and oncologic outcomes in women with advanced stage tubo-ovarian carcinoma in a tertiary cancer center (2022) (0)
- Involvement of DPP9 in gene fusions in serous ovarian carcinoma (2017) (0)
- Abstract 2180: Identification of genomic alterations of human serous ovarian carcinoma with genome-wide integration of copy number and gene expression analysis (2010) (0)
- Abstract 1479: IKK-epsilon contributes to the malignant progression of ovarian cancer (2011) (0)
- Abstract 3052: Ovarian carcinoma derived exosomes: miRNA signatures and role in cancer progression . (2013) (0)
- Supplementary Information for HOTAIR AND ITS SURROGATE DNA METHYLATION SIGNATURE INDICATE CARBOPLATIN RESISTANCE IN OVARIAN CANCER (2015) (0)
- 3 Overview of proteomics with emphasis on diagnosis and monitoring (2004) (0)
- Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). (2022) (0)
- 0292: P53 Mutation is Not Related to Drug Resistant Assays: Analysis of Purified High Grade Ovarian Serous Carcinomas (2006) (0)
- Abstract CT094: Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: Long-term outcome from the ImmunoPeCa phase I/II trial (2018) (0)
- 445 Vulvar verrucous carcinoma: 15 years experience in a single norwegian academic cancer center (2019) (0)
- 209 Prognostic factors related to recurrence and survival of early stage vulvar squamous cell carcinoma (2020) (0)
- Cancer of Other Origin (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ben Davidson?
Ben Davidson is affiliated with the following schools:
